Hilton Santa Fe Historic Plaza Hotel Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2001



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

The Impact of Genomics on Drug Discovery and Development (B5)


Organizer(s) Brian Metcalf, Paul A. Bartlett and Elliott Sigal
February 2—7, 2001
Hilton Santa Fe Historic Plaza Hotel • Santa Fe, New Mexico USA
Abstract Deadline: Oct 2, 2000
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Dec 1, 2000

Sponsored by Bristol-Myers Squibb Pharmaceutical Research Institute and Pfizer Global Research & Development

Summary of Meeting:
The 1990’s saw a revolution in the technologies underpinning drug discovery. Initiated by genomics, the flood of new potential targets to be addressed demanded dramatic changes in target validation strategies followed by paradigm shifts in lead generation approaches. The ability to rapidly amass gene sequence data also spawned new areas post lead discovery - pharmacogenomics and pharmacogenetics. As development candidates move down the drug discovery/development pipelines, readjustment in preclinical development approaches has also been demanded as new technologies impact on safety assessment and drug metabolism. In turn, fundamental changes in approaches to claims in patent applications have occurred without corresponding changes in government patent office policies. As of this writing, while new approaches to lead discovery and optimization are firmly entrenched in the industry, there is not yet an impact of this dislocation of traditional approaches on the composition of clinical portfolios. It will be the general theme of the 2001 Keystone meeting to examine the current status of impact of these new technologies and policies.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


FRIDAY, FEBRUARY 2

14:00—19:00
Registration

Promenade
18:15—19:15
Welcome

Promenade
19:15—19:30
Orientation

Mesa Ballroom
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Mesa Ballroom
* Brian W. Metcalf, Global Blood Therapeutics, USA

Jonathan K.C. Knowles, Caris Life Sciences, Switzerland


SATURDAY, FEBRUARY 3

07:00—08:00
Breakfast

Chamisa/ Pinon Grill
08:00—11:00
Functional Genomics and Target Validation I
Meeting has ended...abstracts no longer viewable online.

Mesa A - B
* Brian W. Metcalf, Global Blood Therapeutics, USA

Geoffrey S. Ginsburg, Duke University, USA
Genomics and the Identification of Novel Targets for Drug Discovery

Christine M. Debouck, Ardennes Biosciences LLC, USA
Applications of Genomics to the Identification and Validation of Novel Targets for Drug Discovery

Kevin Fitzgerald, Alnylam Pharmaceuticals, USA
Animal Model Systems: Target Validation and Target Discovery

Stephen H. Friend, Sage Bionetworks, USA
Genomic Sensor Pads and Pattern Recognition: Impacting both the Discovery and Development of Drugs

09:20—09:40
Coffee Break

Promenade
11:00—13:00
Poster Setup

Mesa C
16:30—18:30
POSTER SESSION 1: Functional Genomics and Target Validation

Mesa C
17:30—18:30
Social Hour with Lite Bites

Promenade
20:00—21:00
Coffee Available

Promenade
20:00—21:15
Functional Genomics and Target Validation II
Meeting has ended...abstracts no longer viewable online.

Mesa A - B
* Jonathan K.C. Knowles, Caris Life Sciences, Switzerland

Steven M. Ruben, Celera Genomics, USA
Acceleration of the Drug Discovery Process Through Genomics

James R. Piggott, Lexicon Genetics, Inc., USA
High-Throughput Phenotypic Analysis in Mice for Drug Discovery

21:15—22:15
Panel Discussion
Meeting has ended...abstracts no longer viewable online.

Mesa A - B
* Paul A. Bartlett, University of California, Berkeley, USA


SUNDAY, FEBRUARY 4

07:00—08:00
Breakfast

Chamisa/ Pinon Grill
08:00—11:30
Impact of New Technologies on Drug Discovery - New Methods and Applications I
Meeting has ended...abstracts no longer viewable online.

Mesa A - B
* Christine M. Debouck, Ardennes Biosciences LLC, USA

N. Leigh Anderson, SISCAPA Assay Technologies,, Inc., USA
The Role of Proteomics

Brian T. Chait, Rockefeller University, USA
Proteomic Approaches to the Elucidation of Protein Interaction, Control, and Function

John G. Houston, Bristol-Myers Squibb Company, USA
Ultra High-Throughput Screening - How Low, How Fast, How Much?

Irwin D. Kuntz Jr., University of California, San Francisco, USA
The Virtual Universe

Arkady B. Khodursky, University of Minnesota, USA
Exploring and Mapping the Living Genome of Escherichia coli

09:20—09:40
Coffee Break

Promenade
11:00—13:00
Poster Setup

Mesa C
16:30—18:30
POSTER SESSION 2: Impact of New Technologies on Drug Discovery – New Methods and Applications

Mesa C
17:30—18:30
Social Hour with Lite Bites

Promenade
20:00—21:00
Coffee Available

Promenade
20:00—21:15
Impact of New Technologies on Drug Discovery - New Methods and Applications II
Meeting has ended...abstracts no longer viewable online.

Mesa A - B
* Paul A. Bartlett, University of California, Berkeley, USA

Patricia C. Weber, Schering-Plough Research Institute, USA
Structural Genomics in Drug Discovery

James A. Wells, University of California, San Francisco, USA
Site-Directed Drug Discovery

21:15—22:15
Panel Discussion
Meeting has ended...abstracts no longer viewable online.

Mesa A - B
* Paul A. Bartlett, University of California, Berkeley, USA


MONDAY, FEBRUARY 5

07:00—08:00
Breakfast

Chamisa/ Pinon Grill
08:00—11:00
What is New in Preclinical Drug Selection? I
Meeting has ended...abstracts no longer viewable online.

Mesa A - B
* Stephen H. Friend, Sage Bionetworks, USA

Donna Mendrick, Food and Drug Administration, USA
Use of Toxicogenomics to Predict Drug Toxicity

Gordon Ringold, Woodside Capital Parnters, USA
Novel Phenotyping Technologies for Target Identification and Biomarker Discovery

Lee E. Babiss, PPD, Inc., USA
High Speed Approaches for Evaluating Preclinical Drug Candidates

Sohaila Rastan, Ceros Ltd., UK
The Use of Model Organisms in Drug Discovery

09:20—09:40
Coffee Break

Promenade
11:00—13:00
Poster Setup

Mesa C
16:30—18:30
POSTER SESSION 3: What is New in Preclinical Drug Selection? / Pharmacogenomics in Practice/Intellectual Property Issues/The Interface of Information Technologies and Life Sciences

Mesa C
17:30—18:30
Social Hour with Lite Bites

Promenade
20:00—21:00
Coffee Available

Promenade
20:00—21:45
What is New in Preclinical Drug Selection? II
Meeting has ended...abstracts no longer viewable online.

Mesa A - B
* Nicholas C. Dracopoli, Janssen R&D Inc., USA

Spencer B. Farr, Phase 1 Molecular Toxicology, USA
Novel Approaches to Phase I Protocols

B. Michael Silber, University of California, San Francisco, USA
Use of Proteomics to Identify Drug Targets and Disease Markers

Christopher A. Lipinski, Chrstopher A Lipinski PhD LLC, USA
Designing Drug-Like Libraries

21:45—22:45
Panel Discussion
Meeting has ended...abstracts no longer viewable online.

Mesa A - B
* Nicholas C. Dracopoli, Janssen R&D Inc., USA


TUESDAY, FEBRUARY 6

07:00—08:00
Breakfast

Chamisa/ Pinon Grill
08:00—10:00
Pharmacogenomics in Practice
Meeting has ended...abstracts no longer viewable online.

Mesa A - B
* James A. Wells, University of California, San Francisco, USA

Michael Kauffman, Karyopharm Therapeutics, USA
Molecular Medicine in Clinical Development and Practice

Michael Wagner, GlaxoSmithKline, USA
Genetically Validated Targets for Discovery; Pharmacogenetics for Development

Cheryl L. Anderson, Bristol-Myers Squibb Company, USA
Pharmacogenomics and the Regulatory Position

09:20—09:40
Coffee Break

Promenade
10:00—12:00
Intellectual Property Issues
Meeting has ended...abstracts no longer viewable online.

Mesa A - B
Terry C. Barrett, Fitzpatrick, Cella, Harper & Scinto, USA
The Generic Battleground and Impact of Hatch/Waxman

Jorge A. Goldstein, Sterne Kessler Goldstein and Fox, USA
Patenting the Tools of Drug Discovery

Maria C. Freire, Global Alliance for TB Drug Development, USA
Implications of Intellectual Property Issues

16:00—17:00
Coffee Available

Promenade
16:00—17:15
The Interface of Information Technologies and Life Sciences
Meeting has ended...abstracts no longer viewable online.

Mesa A - B
* Paul A. Bartlett, University of California, Berkeley, USA

John Couch, Double Twist, USA
Double Twist.com--A Platform for Scientific Research

Charles K. Brush, Motorola Life Sciences, USA
Biochip Systems

17:15—18:00
Concluding Address
Meeting has ended...abstracts no longer viewable online.

Mesa A - B
Nicholas C. Dracopoli, Janssen R&D Inc., USA
The Changing Face of Pharmaceutical R & D

19:00—20:00
Social Hour

Promenade
20:00—22:00
Banquet

Mesa Ballroom
21:00—00:00
Entertainment

Mesa Ballroom

WEDNESDAY, FEBRUARY 7

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 GM62210-01




We gratefully acknowledge additional support for this conference from:

Bristol-Myers Squibb Company

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676